SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
- Mechanism
- Curator reviewed
SR123781A is a synthetic hexadecasaccharide comprising an antithrombin (AT) binding domain, a thrombin binding domain, and a neutral methylated hexasaccharide sequence, was obtained from glucose through a convergent synthesis. SR123781A showed high affinity for human AT and was a potent catalyst of its inhibitory effect with regard to factor Xa and thrombin.
- Primary indication
- Investigated for use/treatment in cardiovascular disorders, thrombosis, and venous thromboembolism.Curator reviewed
- Code names
- SANORG-123781 · SR-123781 · SR-123781A
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with SR-123781A, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account